Shockwave Medical (SWAV) Tops Q1 EPS by 24c, Raises FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall Street ends higher as tech rebounds before Nvidia results
- Oil settles down more than 3%; investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Wall Street ends higher as tech rebounds before Nvidia results
- Intuit (INTU) Tops Q4 EPS; Offers FY27 Guidance
- Oppenheimer Upgrades Capricor Therapeutics (CAPR) to Outperform 'on Approval Optimism'
- Dick's Sporting Goods (DKS) Misses Q2 EPS by 25c, Offers Guidance
Shockwave Medical Reports First Quarter 2023 Financial Results
May 8, 2023 4:02 PM EDTSANTA CLARA, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended March 31, 2023.
Recent Highlights
Recognized revenue of $161.1 million for the first quarter of 2023, representing an increase of 72% from the same period in 2022Announced the full U.S. commercial availability of the Shockwave L6 Peripheral IVL Catheter following clearance by the U.S. Food and Drug... More